Bio-Rad Laboratories Inc (BIO-B)vsJohnson & Johnson (JNJ)
BIO-B
Bio-Rad Laboratories Inc
$279.10
-6.80%
HEALTHCARE · Cap: $8.08B
JNJ
Johnson & Johnson
$229.85
-1.16%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3630% more annual revenue ($96.36B vs $2.58B). BIO-B leads profitability with a 29.4% profit margin vs 21.8%. BIO-B appears more attractively valued with a PEG of 1.21. JNJ earns a higher WallStSmart Score of 59/100 (C).
BIO-B
Buy51
out of 100
Grade: C-
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.5%
Fair Value
$2187.51
Current Price
$279.10
$1908.41 discount
Margin of Safety
-41.6%
Fair Value
$160.43
Current Price
$229.85
$69.42 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
3.9% revenue growth
Earnings declined 83.0%
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : BIO-B
The strongest argument for BIO-B centers on P/E Ratio, Price/Book, Altman Z-Score. Profitability is solid with margins at 29.4% and operating margin at 8.9%. PEG of 1.21 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : BIO-B
The primary concerns for BIO-B are Revenue Growth, EPS Growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
BIO-B profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
BIO-B carries more volatility with a beta of 1.16 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 51/100), backed by strong 21.8% margins. BIO-B offers better value entry with a 86.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?